Market Place
Sourcing Support
Sunovion and Otsuka Initiate Clinical Development of Ulotaront
26 Apr 2023 //
BUSINESSWIRE
Sumitomo Pharma tidies up 7 units into 1 combined U.S. entity
03 Apr 2023 //
FIERCE BIOTECH
Sunovion Answers Is Named a J.D. Power 2022 Certified Customer Service Program?
07 Mar 2023 //
BUSINESSWIRE
Otsuka and Sunovion Initiate Development of Ulotaront for Adjunctive Treatment
01 Dec 2022 //
BUSINESSWIRE
Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn
20 Oct 2022 //
ECONOMIC TIMES
Lupin receives approval from FDA for Arformoterol Tartrate inhalation solution
09 Feb 2022 //
EXPRESS PHARMA
Sunovion and Otsuka Initiate Phase 3 Development of Non-Racemic Amisulpride
09 Feb 2022 //
BUSINESSWIRE
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development
30 Sep 2021 //
BUSINESSWIRE
Sunovion and BIAL Enter European Licensing Agreement
02 Sep 2021 //
BUSINESSWIRE
Sunovion takes Urovant’s OAB med Gemtesa to primary care docs
12 Jul 2021 //
FIERCEPHARMA
AMSA and Sunovion Neuroscience Join hands
30 Jun 2021 //
BUSINESSWIRE
Sunovion Presents Data From Marketed & Late-Stage Develop. Psychiatric Compounds
03 May 2021 //
BUSINESSWIRE
Sunovion Highlights Data from Its Late-Stage Psychiatric Medicine Pipeline
10 Dec 2020 //
BUSINESSWIRE
Angelini Pharma and Sunovion Europe receive EMA approval for Latuda
13 Nov 2020 //
PRNEWSWIRE
Sunovion Marks 10 Years of Addressing Serious Medical Conditions That Impact
26 Oct 2020 //
BUSINESSWIRE
Urovant Sciences Announces Co-Promotion Agreement for Vibegron SunovionPharma
08 Oct 2020 //
PRESS RELEASE
Sunovion Announces the Commercial Launch of KYNMOBI™
03 Oct 2020 //
BIOSPACE
Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service ProgramSM
22 Sep 2020 //
BUSINESSWIRE
Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199
06 Jul 2020 //
BUSINESSWIRE
Sunovion Announces Health Canada Approval of KYNMOBI™
15 Jun 2020 //
BIOSPACE
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride)
27 May 2020 //
BUSINESSWIRE
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride)
23 May 2020 //
BUSINESSWIRE
Parkinson`s patients no longer need to rely on a needle for apomorphine
22 May 2020 //
ENDPTS
Aquestive Advances Royalty Monetization Plan as Sunovion’ Apomorphine
21 May 2020 //
GLOBENEWSWIRE
Sunovion ditches once-rejected ADHD, binge eating program
13 May 2020 //
FIERCE BIOTECH
NEJM Publishes Pivotal Results Evaluating Sunovion’s SEP-363856
15 Apr 2020 //
BUSINESSWIRE
Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
22 Nov 2019 //
BUSINESS WIRE
Sunovion Announces Acceptance by the USFDA of the NDA for Dasotraline
30 Jul 2019 //
BUSINESSWIRE
Astellas, Sunovion and Shield breach ABPI Code
18 Dec 2018 //
PHARMA TIMES
Cerdelga (eliglustat) : Genzyme vs. Apotex
24 Nov 2018 //
PATENT LITIGATION
Latuda® (lurasidone HCl) : Sumitomo D. Pharma, Sunovion vs. Macleods Pharma
22 Sep 2018 //
PATENT LITIGATION
Latuda® (lurasidone HCl) : Sumitomo D. Pharma, Sunovion v. Macleods Pharma USA
13 Sep 2018 //
PATENT LITIGATION
Latuda (lurasidone HCl) : Sumitomo, Sunovion Pharma v. Piramal Healthcare UK
03 Sep 2018 //
PATENT LITIGATION
FDA Issues a CRL for NDA for Dasotraline for the Treatment of ADHD
31 Aug 2018 //
BUSINESSWIRE
FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease
14 Jun 2018 //
DRUG DELIVERY
Sunovion Submits NDA to the FDA for Apomorphine Sublingual Film (APL-130277)
30 Mar 2018 //
BUSINESSWIRE
Aptiom® (Eslicarbazepine Acetate) : Bial - Portela & CA S.A v. Hetero Labs
08 Mar 2018 //
PATENT LITIGATION
Latuda® (Lurasidone HCl): Sumitomo Dainippon Pharma v. Invagen Pharmaceuticals
08 Mar 2018 //
PATENT LITIGATION
Latuda® (Lurasidone HCl): Sumitomo Dainippon Pharma v. Accord Healthcare
08 Mar 2018 //
PATENT LITIGATION
Latuda® (Lurasidone HCl) :Sumitomo Dainippon Pharma v. First Time US Generics
08 Mar 2018 //
PATENT LITIGATION
FDA Grants Sunovion’s Latuda Expanded Approval for Bipolar Depression
06 Mar 2018 //
BIOSPACE
Aptiom® (Eslicarbazepine Acetate) : Bial - Portela v. Jubilant Life Sciences
01 Mar 2018 //
PATENT LITIGATION
Aptiom® (Eslicarbazepine Acetate):Bial - Portela & CA S.A. v. Jubilant
01 Mar 2018 //
PATENT LITIGATION
Aptiom® (Eslicarbazepine Acetate):Bial - Portela & CA S.A. v. Alkem Laboratories
22 Feb 2018 //
PATENT LITIGATION
Latuda® (Lurasidone Hcl): Sumitomo Dainippon Pharma v. Emcure Pharmaceuticals
13 Feb 2018 //
PATENT LITIGATION
Pharma companies fall foul of ABPI’s Code of Practice
14 Dec 2017 //
PHARMA TIMES
Sunovion Announces FDA Acceptance for Review of NDA for Dasotraline for ADHD
13 Nov 2017 //
BUSINESSWIRE
Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance
03 Jul 2017 //
REUTERS
Sunovion`s COPD ambitions dented as FDA rejects phase 3 candidate
31 May 2017 //
BUSINESSWIRE
Sunovion Announces +ve Result from Pivotal Study Evaluating Novel Drug Candidate
24 Apr 2017 //
BUSINESSWIRE
Neurocrine & BIAL Announce North American Licensing Agreement for Opicapone
09 Feb 2017 //
PR NEWSIWRE
Novartis Out-Licenses Three COPD Products in the US
22 Dec 2016 //
PR NEWSWIRE
TV pharma ad spending, AbbVie`s Humira and Pfizer`s Lyrica continue to dominate
07 Nov 2016 //
FIERCE PHARMA
Sunovion pays $624M for Canada’s Cynapsus, lead PhIII Parkinson’s med
01 Sep 2016 //
FIERCE BIOTECH
Massachusetts` Mucus Penetrating Eye Disease Firm Kala Pharma Raises $68 Million
13 Apr 2016 //
BIOSPACE
Fake smiles star in Otsuka and Lundbeck`s DTC push for Rexulti in depression
10 Mar 2016 //
FIERCE PHARMA MARKETING
Sunovion overcomes Section 3(d) objections to obtain patent in India
24 Feb 2016 //
TWOFOUR INSIGHT
AbbVie`s Humira repeats, joined by BMS` Opdivo in leading TV spending
18 Nov 2015 //
FIERCE PHARMA MARKETING
Real-life insomnia stories at core of new Merck-backed awareness campaign
09 Nov 2015 //
FIERCE PHARMA MARKETING
